PRESS RELEASE published on 05/08/2024 at 08:30, 1 year 6 months ago Abivax annonce la présentation de quatre abstracts sur obefazimod dans la rectocolite hémorragique et dans un modèle préclinique de cancer du côlon lors du congrès Digestive Disease Week 2024 Abivax annonce la présentation de quatre abstracts sur obefazimod dans la rectocolite hémorragique et dans un modèle préclinique de cancer du côlon lors du congrès Digestive Disease Week 2024 Abivax Obefazimod Rectocolite Hémorragique Cancer Du Côlon Digestive Disease Week 2024
PRESS RELEASE published on 05/08/2024 at 08:30, 1 year 6 months ago Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024. The event will showcase new data on obefazimod's impact and mechanism of action Abivax Obefazimod Ulcerative Colitis Colon Cancer Digestive Disease Week 2024
BRIEF published on 05/07/2024 at 22:05, 1 year 6 months ago Abivax Announces Availability of Documents for Upcoming General Meeting Biotechnology Shareholder Information Corporate Governance Abivax General Meeting
BRIEF published on 05/07/2024 at 22:05, 1 year 6 months ago Abivax annonce la mise à disposition des documents pour la prochaine assemblée générale Biotechnologie Abivax Assemblée Générale Gouvernance D'Entreprise Informations Pour Les Actionnaires
PRESS RELEASE published on 05/07/2024 at 22:01, 1 year 6 months ago Abivax assemblée générale ordinaire annuelle et extraordinaire du 30 mai 2024 - Mise à disposition des documents préparatoires Abivax annonce la tenue de son assemblée générale annuelle et extraordinaire le 30 mai 2024 à Paris. Mise à disposition des documents préparatoires pour les actionnaires Biotechnologie Abivax Obefazimod Assemblée Générale Documents Préparatoires
PRESS RELEASE published on 05/07/2024 at 22:00, 1 year 6 months ago Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents Abivax informs shareholders of its ordinary and extraordinary general meeting on May 30, 2024, providing access to preparatory documents and details on participation. Obefazimod and Abivax information included Abivax Obefazimod General Meeting Clinical-stage Biotechnology Preparatory Documents
PRESS RELEASE published on 05/07/2024 at 22:00, 1 year 6 months ago Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents Abivax announces its annual ordinary and extraordinary general meeting on May 30, 2024, with preparatory documents available for shareholders. The meeting details, including agenda and resolutions, are accessible on the company's website Shareholders Biotechnology Abivax General Meeting Preparatory Documents
PRESS RELEASE published on 05/07/2024 at 22:00, 1 year 6 months ago Abivax assemblée générale ordinaire annuelle et extraordinaire du 30 mai 2024 - Mise à disposition des documents préparatoires Abivax annonce son assemblée générale annuelle et extraordinaire du 30 mai 2024 avec la mise à disposition des documents préparatoires. L'événement se tiendra à Paris Biotechnologie Abivax Assemblée Générale Traitements Thérapeutiques Documents Préparatoires
BRIEF published on 04/30/2024 at 18:05, 1 year 7 months ago ABIVAX rapporte le nombre d'actions et de droits de vote au 31 mars 2024 Autorité Des Marchés Financiers Droits De Vote Capital Social Abivax Informations Réglementaires
BRIEF published on 04/30/2024 at 18:05, 1 year 7 months ago ABIVAX reports the number of shares and voting rights as of March 31, 2024 Share Capital Voting Rights Financial Markets Authority Abivax Regulatory Information
Published on 12/06/2025 at 01:15, 42 minutes ago Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 1 hour 32 minutes ago GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 1 hour 57 minutes ago Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 2 hours 27 minutes ago 55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 22:15, 3 hours 42 minutes ago CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 3 hours 45 minutes ago EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 6 hours 59 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 7 hours 42 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 23:00, 2 hours 57 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 2 hours 57 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 2 hours 57 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 2 hours 57 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 8 hours 39 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible